Jan 10, 2023 / 12:30AM GMT
James Daniel Gordon - JPMorgan Chase & Co, Research Division - Senior Analyst
Good afternoon. I'm James Gordon, J.P. Morgan European Pharma and Biotech Analyst. And today, I've got the pleasure of introducing the Galapagos presentation. So, you're going to hear from Galapagos CEO, Paul Stoffels and we're going to have a 20-minute Q&A in this room after the presentation.
So with that said, thanks a lot for joining us today, Paul. Looking forward to the presentation.
Paulus A. Stoffels - Galapagos NV - CEO, Chairman, Head of R&D & Member of Management Board
Good afternoon. My name is Paul Stoffels. As said, I'm the CEO of Galapagos. After retiring from J&J, where I worked for 30 years as mainly in the science, but as Chief Scientific Officer for the last 10 years, returned back to Europe and took the reins of a company, which I co-founded back in '98. And so it was going back home for me, recharging Galapagos for the future. And so, I'll give you a short summary of the story, what we are doing at the moment and the new products, new
Galapagos NV at JPMorgan Healthcare Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers